SCHEMBL3025671

SCHEMBL3025671

CCCCNC1=CC(=O)OC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.43
ALDH1A1 P00352 4/20 0.38
APAF1 O14727 1/20 0.38
LMNA P02545 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HTT P42858 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
POLB P06746 1/20 0.37
CA1 P00915 1/20 0.36
CA9 Q16790 1/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
ELANE P08246 3/20 0.34
HCAR3 P49019 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3031090 0.89 LMNA (0.46) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3036907 0.81
SCHEMBL10963604 0.75 ALDH1A1 (0.49) MAPTALDH1A1APAF1LMNAMEN1
SCHEMBL3039544 0.73 MAPT (0.40) MAPTALDH1A1L3MBTL1POLBCA1
SCHEMBL3036155 0.67 POLB (0.53) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL7524303 0.66
SCHEMBL23312214 0.66 MAPT (0.37) MAPTALDH1A1APAF1LMNAMEN1
SCHEMBL24849580 0.66 PDCD4 (0.39) CA1CA9GPR84
SCHEMBL28362540 0.66 MAPT (0.88) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL24023289 0.66 PDCD4 (0.36) CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101801913-B Method for producing 4-aminobut-2-enolides BAYER CROPSCIENCE AG 2014-06-11 CN disclosed
EP-2203410-B1 METHOD FOR PRODUCING 4-AMINOBUT-2-ENOLIDES BAYER CROPSCIENCE AG (DE) 2014-03-26 EP disclosed
EP-2253610-B1 Method for manufacturing of enaminocarbonyl-compounds and their use in preparing 4-aminobut-2-enolids BAYER CROPSCIENCE AG (DE) 2013-11-20 EP disclosed
US-8487112-B2 Method for producing 4-aminobut-2-enolides BAYER CROPSCIENCE AG (DE) 2013-07-16 US disclosed
EP-2253610-A1 Method for manufacturing 4-aminobut-2-enolids Bayer CropScience AG (DE) 2010-11-24 EP disclosed
US-20100204480-A1 METHOD FOR PRODUCING 4-AMINOBUT-2-ENOLIDES BAYER CROPSCIENCE (DE) 2010-08-12 US disclosed
EP-2203410-A1 METHOD FOR PRODUCING 4-AMINOBUT-2-ENOLIDES Bayer CropScience AG (DE) 2010-07-07 EP disclosed
WO-2009036898-A1 METHOD FOR PRODUCING 4-AMINOBUT-2-ENOLIDES BAYER CROPSCIENCE AG (DE) 2009-03-26 WO disclosed
EP-2039678-A1 Method for manufacturing 4-aminobut-2-enolids Bayer CropScience AG (DE) 2009-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204480-A1 METHOD FOR PRODUCING 4-AMINOBUT-2-ENOLIDES CYP4B1, TUBB4B, EIF4B MAPT 2689/4885ALDH1A1 468/4885APAF1 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.